FlandersBio on Twitter

Follow us on Twitter

Archive for June 2011 - News

Archive for June 2011 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Ablynx initiates a Phase I study for ALX-0651, the first Nanobody in clinical development targeting


Ablynx [Euronext Brussels: ABLX] today announced that it has initiated a Phase I clinical trial in healthy volunteers with ALX-0651, an anti-CXCR4 Nanobody, for use in stem cell mobilisation. ALX-0651 is the first Nanobody in clinical trials targeting a GPCR, a target class that has proven to be difficult to address with conventional antibodies. It is the second Nanobody that has entered clinical development this year, which brings the total number of Nanobodies in the clinic to seven. read more

Argenta signs integrated services agreement with Pulmagen Therapeutics


Mechelen, Belgium; 28 June 2011 – Galapagos NV (Euronext: GLPG) announced today that service division Argenta has signed a subcontracting agreement with Pulmagen Therapeutics Limited to perform integrated services on two respiratory projects. read more

Ablynx receives eur 5 million in milestone payment from alzheimer's disease collaboration with Boehringer Ingelheim


Ablynx [Euronext Brussels: ABLX] today announced that it has earned a €5 million milestone payment following Boehringer Ingelheim’s decision to initiate development with the lead Nanobody candidate that was selected in May 2010. read more

IWT helps to accelerate reMYND’s Diabetes program with a grant of 1.48 million EUR for 2011-2012


reMYND NV today announced that it has received a grant of 1.48 million EUR from IWT, the Flemish agency for Innovation by Science and Technology, to accelerate its Diabetes program. reMYND announces this news during the Bio International Convention (Washington, US) on 27 June 2011. read more

President Pedro Pires visits the Jatropha curcas R&D center of Agriverde and QUINVITA in Cape Verde


On June 24th at 16:30, the President of the Republic of Cape Verde, Mr. Pedro PIRES will visit Jatropha curcas (‘’purgueira’’) R&D station of Agriverde and QUINVITA in Sao Domingos, Cape Verde. He will be received by the Cape Verdean and Dutch private partners in Agriverde, by the senior management of QUINVITA and by the Dutch Ambassador Mr. Gerben DE JONG. read more

QUINVITA and K.U.Leuven receive 715,000 EURO grant from IWT


The Industrial Crop Technology Company, QUINVITA announced today it received a grant of 715,000 EURO from the agency for Innovation by Science and Technology in Flanders (IWT). The grant allows QUINVITA and the team of Professor Bart Muys at the Catholic University of Leuven (K.U.Leuven) to establish a detailed R&D program on the agronomy and genetics of Jatropha curcas. read more

Roche ontvangt Vlaamse biotechdelegatie onder leiding van Vlaams Minister-president Kris Peeters


Vrijdag a.s. 24/06/2011 vindt een officieel bezoek plaats van onze Vlaamse biotechbedrijven, in de aanwezigheid van Vlaams Minister-President Kris Peeters, bij Roche, New Jersey. Aanleiding van dit bezoek zijn de samenwerkingen tussen de wereldspeler Roche en onze Vlaamse biotechparels ThromboGenics en reMYND. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top